Compare ARK Genomic Revolution ETF (ARKG) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Main Street Capital Corporation — how do they compare? ARK Genomic Revolution ETF trades at $44.29, while Main Street Capital Corporation trades at $59.01 (market cap $5.47B). The key difference: Main Street Capital Corporation pays a 5.43% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Main Street Capital Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | MAIN | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $44.55 | $67.54 |
52-Week Low | $24.02 | $49.63 |
Market Cap | — | $5.47B |
Dividend Yield | — | 5.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
Main Street Capital (MAIN) trades at $58.94, up 3.79% with strong technical momentum. The stock shows bullish technical signals with support at $57 and resistance at $60. Recent Q2 2026 earnings beat expectations at $0.97 per share, though Q1 missed. The company maintains an 80.77% net income margin with consistent dividend payments, positioning it as a reliable income stock. Revenue trends show slight moderation from 2024's peak but remain above 2022-2023 levels.
Outlook remains positive given MAIN's strong profitability and dividend consistency, though near-term risks include expense pressures impacting earnings coverage and broader market volatility. Analyst consensus leans cautious with 78.57% hold ratings, suggesting limited upside from current levels despite the stock's technical strength and income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
